This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
by Kinjel Shah
Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.
NVONegative Net Change LLYNegative Net Change ALTNegative Net Change MDGLNegative Net Change
biotechs
BEAM Eyes Global Expansion of AATD Study After Strong Early Data
by Zacks Equity Research
Beam Therapeutics reports promising phase I/II data for BEAM-302 in AATD, showing strong efficacy, tolerability and potential as a one-time curative treatment.
BEAMNegative Net Change CPRXNegative Net Change INOPositive Net Change ADMAPositive Net Change
biotechs
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
by Kinjel Shah
Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.
NVONegative Net Change LLYNegative Net Change ALTNegative Net Change
biotechs
ALT Pemvidutide Explained: What Makes It Different in MASH
by Kinjel Shah
Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.
NVONegative Net Change LLYNegative Net Change ALTNegative Net Change MDGLNegative Net Change
biotechs
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
by Kinjel Shah
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
AZNPositive Net Change NVSNegative Net Change JNJPositive Net Change PFENegative Net Change MRKPositive Net Change VSTMNegative Net Change XLONegative Net Change
biotechs cancer
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
by Zacks Equity Research
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
NVONegative Net Change CPRXNegative Net Change INOPositive Net Change ADMAPositive Net Change
biotechs
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
by Zacks Equity Research
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
ANIPNegative Net Change REPLNegative Net Change OCGNNegative Net Change PHATNegative Net Change
biotechs
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
by Zacks Equity Research
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
REGNNegative Net Change SNYPositive Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
by Ekta Bagri
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
by Zacks Equity Research
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.
NVSNegative Net Change INCYNegative Net Change CPRXNegative Net Change KPTINegative Net Change
biotechnology biotechs medical pharmaceuticals